Business Wire

GNT-PHARMA

Share
GNT Pharma Announces Positive Top-Line Results in a Phase II Study of Nelonemdaz for Acute Ischemic Stroke Patients Treated With Endovascular Thrombectomy

GNT Pharma Inc. today reports positive top-line results from a phase II, double-blind, randomized, placebo-controlled, multi-center study assessing the safety and efficacy of nelonemdaz in acute ischemic stroke patients treated with endovascular thrombectomy within 8 hours of symptom onset (SONIC). In this study, the addition of nelonemdaz to surgical blood clot removal improved a patient’s chances of returning to functional independence 90 days later.

Nelonemdaz is a moderate NR2B-selective N-methyl d-aspartate (NMDA) receptor antagonist and potent spin trapper that reduces NMDA receptor-mediated excitotoxicity and oxidative stress, two major routes of brain cell death leading to disability and death after stroke. Nelonemdaz previously showed better efficacy and a longer therapeutic time window than subtype-unselective NMDA antagonists or antioxidants alone in 5 animal models of stroke. Its safety and tolerability in humans has been established in two earlier phase I studies conducted in 165 healthy young and elderly volunteers in the US and China.

SONIC enrolled 209 moderate to severe ischemic stroke patients (NIH Stroke Scale of 8 or higher) at 7 university stroke centers in South Korea. Patients received a 1st infusion of placebo, 500 mg nelonemdaz (low dose group), or 750 mg nelonemdaz (high dose group) prior to thrombectomy. Low dose and high dose groups then received 9 follow-up infusions of 250 mg and 500 mg nelonemdaz, respectively, at 12 hour intervals. The primary outcome was the fraction of patients with good functional outcome (no more than slight disability, able to look after own affairs without assistance) 90 days later, defined as a score of 0-2 on the modified Rankin Scale (mRS), the most widely used outcome measure in stroke studies. In the low dose nelomendaz group, 33 of 55 patients (60.0%) group achieved good functional outcome, and in the high dose nelomendaz group, 31 of 49 patients (64.6%) achieved good functional outcome, compared to 25 of 49 patients (51.0%) in the placebo group. The fraction of patients achieving near-complete recovery (mRS score 0) was markedly increased in nelonemdaz-treated groups, with 23.6% of the low dose group and 33.3% of the high dose group achieving no significant disability 90 days later, compared to only 8.2% of the placebo group. No serious adverse events of nelonemdaz were observed.

“Compared to placebo, administration of nelonemdaz increased the chances of achieving a good functional outcome by more than 20% in moderate to severe ischemic stroke patients who received endovascular thrombectomy”, said Dr. Byoung Joo Gwag, CEO and founder of GNT Pharma and inventor of nelonemdaz. “And it more than tripled chances of achieving a near-complete recovery. Over the last 3 decades, many NMDA antagonists and antioxidant drugs have failed in clinical stroke trials, despite showing efficacy in animal models of stroke. Such failed trials were probably due to the adverse effects of subtype-unselective NMDA receptor antagonists, or the limitations of targeting single injury mechanisms. SONIC was the first clinical trial of our novel multitarget neuroprotectant, nelonemdaz, administered to ischemic stroke patients who also received endovascular recanalization, which has recently become a standard of stroke care.”

Dr. Dennis W. Choi, a professor of neurology at the State University of New York, Stony Brook, a pioneer in the stroke neuroprotection field, and a scientific advisor to GNT Pharma, commented “these are very encouraging phase II results that heighten interest in seeing the results of larger phase III trials.”

In a companion phase II study with 237 acute ischemic stroke patients conducted in China, nelonemdaz was well tolerated and benefitted patients who were treated with thrombolytic drugs within 8 hours of symptom onset. A phase III study of nelonemdaz for 948 ischemic stroke patients treated with a thrombolytic drug has just begun in China.

Current observations of nelonemdaz in acute ischemic stroke patients receiving recanalization therapies promises to open up a new era of neuroprotection therapy for the treatment of stroke.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release

With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp

Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release

The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev

7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release

MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t

First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release

Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American

Deltatre Announces Acquisition of Endeavor Streaming to Create Digital and Streaming Platform Leader15.7.2025 16:15:00 CEST | Press release

Deltatre, a leading international provider of streaming, digital, data, and graphics solutions for the sports, media, and entertainment industries, today announced it has entered into a definitive agreement to acquire Endeavor Streaming from Endeavor Group Holdings, Inc. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715833650/en/ Deltatre announces acquisition of Endeavor Streaming. In bringing together these complementary and proven digital and OTT providers, Deltatre is joining its advanced product suite – D3 VOLT, FORGE, AXIS, and DIVA, which delivers multi-functional digital experiences with integrated video – with Endeavor Streaming’s pure-play OTT product, VESPER. They will also unite their digital strategy, consulting, and direct-to-consumer growth marketing services. The combined business will be best equipped to deliver for sports, media, and entertainment clients through a compelling and comprehensive range of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye